Overwatch secures oversubscribed funding

Life science software company Overwatch has closed a significant funding round that will accelerate product development and enable the company to grow its existing customer portfolio across both Europe and the USA.
Graham Wilsdon, Paul Wilsdon and Chris Armstrong celebrate funding boostGraham Wilsdon, Paul Wilsdon and Chris Armstrong celebrate funding boost
Graham Wilsdon, Paul Wilsdon and Chris Armstrong celebrate funding boost

The investment has been led by Techstart Ventures and includes a number of NI-based private investors who are part of the Halo Business Angel Network (HBAN). The funding round was oversubscribed demonstrating strong investor interest in high-potential start-ups despite the current economic uncertainty.

Overwatch, based in Ormeau Baths, Belfast is an innovative software company revolutionising drug development processes for pharmaceutical companies worldwide. The product reduces scientific error and inefficiencies, helping to solve the global reproducibility crisis which costs the pharmaceutical industry $28Bn every year in the USA alone. This pre-clinical reproducibility crisis is a major contributory factor to the unacceptably high clinical trial failure rate.

Hide Ad
Hide Ad

Over the past year, Overwatch has built a portfolio of customers and partnerships on both sides of the Atlantic, helping pharmaceutical companies develop drugs for some of the world’s most prominent diseases including cancer and Alzheimer’s.

Overwatch CEO, Dr Chris Armstrong, said: “We are delighted to close this investment round and look forward to pursuing ambitious targets relating to both product and sales. We are especially thankful to both Techstart and our private investors for supporting us during this unprecedented time of economic uncertainty. This funding will enable us to develop our relationship with current customers and establish new professional partnerships within the pharmaceutical and contract research industries.”

Techstart Venture’s Investment Director, John Murray added: “The Overwatch solution solves problems confronting researchers and was borne out of Chris’ own experience as a cancer researcher. Chris and his co-founders, Paul and Graham Wilsdon, have built a world-class product that is now being used in both Europe and the USA to help researchers ultimately find cures for disease. We’re delighted to support the Overwatch team as they enter an exciting new growth phase.”

HBAN representative, Chris Trotter, said: “Overwatch attracted significant interest among our investor group who recognised the potential for innovative software in the drug development process. The team have an exciting journey ahead as they execute an ambitious international growth plan.”

A message from the Editor:

Hide Ad
Hide Ad

Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.

In order for us to continue to provide high quality and trusted local news on this free-to-read site, I am asking you to also please purchase a copy of our newspaper whenever you are able to do so.

Our journalists are highly trained and our content is independently regulated by IPSO to some of the most rigorous standards in the world. But being your eyes and ears comes at a price. So we need your support more than ever to buy our newspapers during this crisis.

With the coronavirus lockdown having a major impact on many of our local valued advertisers - and consequently the advertising that we receive - we are more reliant than ever on you helping us to provide you with news and information by buying a copy of our newspaper when you can safely.

Hide Ad
Hide Ad

You can also enjoy unlimited access to the best news from across Northern Ireland and the UK by subscribing to newsletter.co.uk

With a digital subscription, you can read more than five articles, see fewer ads, enjoy faster load times, and get access to exclusive newsletters and content. Visit https://www.newsletter.co.uk/subscriptions now to sign up.

Thank you

Related topics: